KMB:NASDAQKimberly-Clark Corporation Analysis
Data as of 2026-03-10 - not real-time
$101.88
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Kimberly‑Clark (KMB) is trading at $101.88, barely above its 20‑day SMA of 107.61 and well below the 200‑day SMA of 117.64, indicating a lingering weakness in the long‑term trend. The RSI of 38 hints at modest oversold pressure, while a bearish MACD histogram reinforces short‑term downside bias. Dividend yield remains attractive at nearly 5% but the payout ratio exceeds 100%, raising sustainability concerns. Recent material news – a shareholder‑approved acquisition of Kenvue and the appointment of Francesco Tinto as CIO/GBS Officer – could unlock volume‑driven growth, yet integration risk adds uncertainty. The DCF fair value of $17.53 suggests the market is heavily overvalued, with an implied upside/downsides of about 17% relative to current pricing.
Overall, KMB offers defensive exposure and strong cash generation, but the combination of overvaluation, high payout, and modest growth tempers enthusiasm. Investors should weigh the short‑term price weakness against the long‑term dividend pedigree and potential synergies from the Kenvue deal.
Overall, KMB offers defensive exposure and strong cash generation, but the combination of overvaluation, high payout, and modest growth tempers enthusiasm. Investors should weigh the short‑term price weakness against the long‑term dividend pedigree and potential synergies from the Kenvue deal.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering near immediate support at $101.02
- Bearish MACD signal
- High dividend yield but unsustainable payout
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential revenue uplift from Kenvue integration
- Defensive consumer‑staples positioning
- Continued overvaluation relative to DCF
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Dividend‑king status with >50 years of increases
- Stable cash flow and low beta
- Uncertainty around long‑term earnings growth and valuation gap
Key Metrics & Analysis
Financial Health
Revenue Growth-0.60%
Profit Margin12.29%
P/E Ratio21.0
ROE126.60%
ROA9.61%
Debt/Equity464.79
P/B Ratio22.5
Op. Cash Flow$2.8B
Free Cash Flow$912.9M
Technical Analysis
TrendNeutral
RSI38.3
Support$101.02
Resistance$111.82
MA 20$107.61
MA 50$103.33
MA 200$117.64
MACDBearish
VolumeStable
Fear & Greed Index77.54
Valuation
Fair Value$17.53
Target Price$119.21
Upside/Downside17.01%
GradeOvervalued
TypeValue
Dividend Yield4.98%
Risk Assessment
Beta0.06
Volatility23.44%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.